Pfizer bets $5.4bn against gene therapies in sickle cell
Hopefully the acquisition of Global Blood Therapeutics will go better than Pfizer’s last foray into sickle cell deal-making.
EHA 2022 – Crispr still looks bloody good
Updated data with exa-cel in sickle cell disease and beta-thalassaemia could put the fear into competitors.
A big year for sickle cell
Novel approaches including gene editing are creeping towards approval.
Agios’s pricing dilemma
How can the company wring the most value from Pyrukynd?
Imara gets a second shot in sickle cell
Will upping the dose and changing the primary endpoint pay off?
Your 2022 wildcard predictions revealed
Could Aduhelm be pulled? Will Incyte get acquired? Here are some of your wildest New Year predictions.
Ash 2021 roundup
Evaluate Vantage's coverage of the Ash 2021 congress.
Ash 2021 movers – IGM steals the show, for all the wrong reasons
At a meeting lacking practice-changing studies and featuring many disappointments the downturn in IGM’s fortunes stands out.